Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are gaining popularity in Armenia as an increasing number of people are diagnosed with respiratory diseases.
Customer preferences: Bronchodilator drugs are preferred by people suffering from respiratory diseases such as asthma, bronchitis, and emphysema. These drugs provide relief by relaxing the muscles in the airways, making it easier to breathe. Patients prefer bronchodilator drugs as they provide quick relief from symptoms such as coughing, wheezing, and shortness of breath.
Trends in the market: The Bronchodilator Drugs market in Armenia is witnessing a steady growth due to the increasing prevalence of respiratory diseases. The market is dominated by short-acting bronchodilators, which provide quick relief from symptoms. However, long-acting bronchodilators are gaining popularity as they provide sustained relief and are more convenient to use. Combination therapies, which combine bronchodilators with other drugs such as corticosteroids, are also gaining popularity in the market.
Local special circumstances: Armenia has a high prevalence of respiratory diseases, which is driving the demand for bronchodilator drugs. The country has a high level of air pollution, which is a major contributor to respiratory diseases. In addition, Armenia has a high smoking rate, which is another major risk factor for respiratory diseases. The government has taken steps to reduce air pollution and smoking rates, which is expected to have a positive impact on the market in the long run.
Underlying macroeconomic factors: Armenia is a developing country with a growing economy. The healthcare sector is a priority for the government, and significant investments have been made in improving healthcare infrastructure and services. The government has also implemented universal healthcare, which provides access to healthcare services to all citizens. This has increased the demand for healthcare services, including bronchodilator drugs. In addition, the growing middle class in Armenia has increased the affordability of healthcare services, which is driving the demand for bronchodilator drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
